


Navigating Adverse Event Reporting

Andrea Pointer, MLS (ASCP)^{CM}

Transfusion Services Supervisor

University Health Kansas City

Truman Medical Center and Lakewood Medical Center



Objectives

Case presentation

Brief Review of
Transfusion
Reactions

Transfusion
Reaction
Workups

Adverse Event
Reporting
Overview



What did the
FDA ask of us?

Unexpected
emotional
toll



Patient presentation

- 27 y/o M presented to the ED with abdominal pain, jaundice, and recent appearance of red blood in stool.
- Initial labs and radiology supported diagnosis of multiple alcohol-related disease states, including cirrhosis, coagulopathy, AKI, lactic acidosis
- Coagulopathy assessed by TEM and standard coagulation panel
 - Admit labs: PT 29, INR 2.59, aPTT 81.3
- 1 adult dose of Cryoprecipitate and 1 unit Fresh Frozen Plasma Ordered and prepared.



Patient presentation, continued

- All three bags of product were dispensed at 14:19
- Patient vitals and pre-transfusion assessment completed; patient tachycardic at 108 bpm
- Bag 1 of Cryo transfusion completed at 14:38
- Patient reported feeling anxious and heart rate had increased to 135. RN reports visible restlessness and called Med team at 14:40.
- By 14:42, patient was in asystole. RN began CPR and called the Code Blue.
 - Chart notes indicate rash may have been present about face and neck, but reports could not be confirmed



Patient presentation, continued

- Patient successfully resuscitated.
- Transfusion reaction investigation initiated.
 - Primary investigation is intended to discover potential clerical error, collection/typing error, other bench testing error, product mismatch, comparisons of pre and post transfusion samples (DAT, hemolysis, icterus, blood types, sometimes repeat antibody screen), who in the medical team was notified/responded, is it safe to continue transfusions, and finally, sign off by Transfusion Services Medical Director, or their Designee, upon review.
 - No technical or clinical error was found.
 - Preliminary Pathology Case consult added to patient EMR
 - Spent bag of cryo + un-transfused bag of cryo returned to blood supplier for further testing.

What is the relationship of this clinical event to the half-dose of Cryoprecipitate transfusion?



Patient presentation, continued

- What happened next??
 - Nothing, really, until 2 days after initial cardiac event.
 - The goal had changed to support through acute events until stabilized, then address chronic GI bleeding from varices.
 - After finding moderate amount of free abdominal fluid and patient stopped producing urine dialysis was required.
 - During the procedure to obtain dialysis access, patient desaturated to 30% with BP 40/20. Patient did not lose pulse, and was resuscitated again, though in clear organ failure.
- Call for Help
 - CBC Medical Director Consulted
 - Anaphylactic reaction is most likely, since it is the only one leading to arrest AND presents with rash.
 - Determined avoidance of transfusion is best, offer washed products if absolutely necessary, run pre-transfusion IgA level
 - Individual factor medication could be best, but may also be at risk for anaphylaxis.
 - Heme/Onc consulted for recommendations
 - Advised to hold off all transfusion as long as patient is not worsening.



Help is on the way, Dear!



Types of Reactions

Febrile non-hemolytic

Acute Hemolytic

Bacterial
Contamination

Fever

Anaphylaxis
(potential for IgA
deficiency + anti-IgA)

Urticaria

Allergic

TACO and TRALI

Hypoxemia/Dyspnea

TA-GvHD

Post-transfusion
purpura

Transfusion-related
alloimmune
neutropenia

Cytopenias

Acute Hemolytic
Reaction

Delayed Hemolytic
Reaction

Non- RBC Antibody-
mediated hemolysis

Hemolysis

UNCOMMON

Can result in fever,
tachycardia, and/or
hypotension

Infection



Types of Reactions

Usually
bradykinin
mediated; systolic
drop ≥ 30 mmHg or
systolic < 80 mmHg

Hypotensive

Usually only
found in
chronically-
transfused or
with underlying
disease.

Iron Overload

Antibody
formation
without positive
DAT or evidence
of hemolysis

Delayed Serologic



Anaphylaxis

This HAS to be the cause, right?

- Maybe?
 - Mechanism of action is related to IgE/mast cell activation, haptoglobin deficiency, or IgA deficiency with anti-IgA.
- Patient never experienced severe allergies or asthma in early life. Histamine is known to be a vasoDILATOR, and arrest is due to vasoconstriction.
- Post-transfusion IgA level result was on the high side of normal range. Haptoglobin was low-normal.
 - But wait, the patient received a unit of FFP, so this could be donor IgA detected, and not patient IgA.
 - **EXCEPT** by this point, Medical Staff members present during the code had been interviewed individually, and we learned the MD leading the initial code instructed a RN to 'just throw it out'. This was not in the EMR.
- This must mean either Cryo contains a ridiculously high level of IgA since half an adult dose could create a high/normal reading in an assumed deficient patient.



Or, IgA is not implicated, and cardiac arrest was due to.....????



Cardiac Arrest and Acidosis

This was determined to be the ultimate cause of death.

- Unfortunately, the patient did not regain consciousness, experienced worsening organ function, and was moved from full code to comfort measures after losing basic reflexes.
- Lactic acidosis is common with liver failure
 - Lactate is cleared from circulation by healthy liver tissue
 - Low blood pH is known to contribute to vasoconstriction



Adverse Reaction Governance

- AABB
 - Standards, Chapter 7 (entirely)
 - Addresses issues in manufacturing, nonconformance to SOP (if affecting safety, purity, or potency of product), classifying events, actions specific for suspected hemolytic reactions
 - 7.2 Fatality Reporting
 - Fatalities confirmed to be caused by... transfusion shall be reported to outside agencies as required.
- TJC
 - Standards addressing adverse event reporting include Process Improvement, Leadership, Quality Systems Assessment
 - PI.01.01.01 EP7, LD.03.07.01 EP2, LD.03.09.01, QSA.05.18.01, QSA.05.19.01, QSA.05.19.03
 - Standards direct facilities to utilize specialty-specific governing resources (basically, TJC directs Transfusion Services to AABB Guidelines and does not have extensive oversight)
 - *Anecdote:* Survey review included reporting clerical check, DAT, specimen collection info, review vitals, transfusion details (start-stop, volume transfused, and “reaction observed?”), was it fully reviewed by the Medical Director of Transfusion Services, prove the results were viewable by medical team.
- CAP
 - TRM.41650, 41750, 41770, 41800, **41850**, 42000, 42050, 42060
 - Match AABB guidelines closely



Transfusion Reaction Workups

- Combining requirements of all standards reviewed, reaction workups must address:
 - Inspecting blood container, including accompanying tubing/infusion sets and IV solutions; Labeling should be inspected for accuracy and appropriateness (correct patient, correct product)
 - Clerical checks of all pre-transfusion testing and activities
 - Evaluation of pre and post-transfusion samples for hemolysis
 - Bench tests on post-transfusion sample:
 - DAT for C3 and IgG, repeat ABO
 - May compare to pre-transfusion, if positive or unexpected result obtained
 - Potential cultures?
 - Documented date/time of Physician review (Pathologist)/ interpretation of Medical Director
- Suggest further investigation, if
 - Fatality occurs, clerical error found, discrepancy in blood types, unexpected lab results obtained during workup
 - Repeat pre-transfusion testing, antibody testing on post-transfusion sample, AHG crossmatch, antigen typing, urinalysis and free hgb, liver studies, LDH, haptoglobin, unit examination, cultures



FDA Center for Biologics Evaluation and Research

- Pre-event SOP
 - If fatality occurs and is related to transfusion, notify CBER within 24 hours of the death.
 - Complete a written report within 7 days.
 - That was it.
 - Lab called the lawyers.
- Enter “Notifying the FDA...” Guidance for Industry.
 - If fatality occurs as a result of transfusion reaction, report must be made by the facility that performed compatibility testing (note – the responsibility could be shared, depending on facility and product manufacturer relationship).
 - Initial notification from Recipient Facility to include...
 - Date/Time of the notification
 - Reporter’s info (facility, title, contact info, FDA number if you have one)
 - Patient demographics and brief details of the event
 - Patient medical history/current disease states necessitating transfusion
 - Product details, including unit number and manufacturer demographics.
 - FDA suggests email reporting, as the response is custom and easy to track.



What did they ask of us?

Quite a lot, actually.

**Complete transfusion reaction
report**

**Recalls associated with ALL
products used**

Physician consults

Transfusion records

Death Certificate

**Details of the blood collection
system**

**Infectious disease test results
(this stay or ever)**

Radiology reports

**Minutes from Transfusion
Committee review**

Corrective Action Plans

**All relevant labs, differentiating
admission and post-transfusion
values**

Discharge Summaries

**All investigation steps and
conclusions**

Admission notes

...and no suggestion on
the format or approach
to compile and report



Did you know you have SEVEN DAYS?

- At my facility, the transfusion reaction workup was designed to identify a Hemolytic reaction.
 - Transfusion Reaction Pathology Consult further defines classification of the reaction to allergic, febrile, etc., in a formal manner.
 - LIS build was not intended to translate to a written report, so emergency IT ticket to address building a report.

Reported To	
Date & Time Reported to Dr.	1440
Reported By:	
Unit Number	
Date & Time Return	08/23/2024 17:00
Amount Return	< 1.0 ml
Date & Time Issued	08/23/2024 14:19
Receipient	Agreement
Unit(s)	Agreement
XM label(s)	Agreement
Clerical Error	N
Pre-Hemolysis	N
Post-Hemolysis	N
Pre-Icterus	Y
Post-Icterus	Y
Anti-A	0
Anti-B	0

zReported to	
Date & Time Reported to Dr.	1440
Reported by:	See Below ^{T8}
Post-I ABORH	O POS
Trxn Interp	See Below ^{T9}
Post-DAT Interp	Negative

Textual Results

T6: 8/23/2024 18:25 CDT (Current Medication)
see MAR

T7: 8/23/2024 18:25 CDT (Symptoms)
restless, AMS, asystole

T8: 8/23/2024 18:25 CDT (Reported by:)
[redacted]

T9: 8/23/2024 18:25 CDT (Trxn Interp)
No Evidence of Hemolytic Transfusion Reaction



*Did you know you have **four DAYS?***

- Call for an Urgent Case Review
 - Invited entire Transfusion Committee (reps all specialties)
 - Included Hematology/Oncology, due to extensive consult
 - Legal Team
 - Found there was no formal process for conducting or documenting a case review
- We chose Morbidity and Mortality Conference format.
 - Peer-review that seeks to identify systemic improvement over placing blame.
 - Conducted case review, lab and radiology records review, differential diagnosis of transfusion reaction(s), product analysis
 - Minutes recorded on general word processing template.



Did you know *you have three days?*

- Final report composed by Legal Department.
 - Format chosen was legal memo
 - Memo began with statement of the fatality
 - “The fatality occurred (at this address on this date). The patient involved is (de-identified description). The cause of death was determined to be...”
 - Very brief overview of the event
 - “Patient was ordered to receive (blood products) prior to (procedure) and experienced (this reaction)”
- Details were given in a bulleted list, to include
 - Underlying medical conditions necessitating hospitalization, Reason for transfusion, product(s) involved, Products administered AFTER transfusion reaction, Patient response to treatments and medical interventions,
 - Minutes recorded on general word processing template.




FDA Center for Biologics Evaluation and Research

- Over 6 MB of data was emailed to the FDA as requested.
- The refused to access encrypted email.
- Over 6 MB worth of printed materials was faxed to the FDA as requested.
- We received confirmation of information received, but have not received additional feedback to date.



Final thoughts



Advice for workplace grief

- Our work is in saving lives.
 - Grief and loss can hit secondary caregivers in the “shouldn’ts”
- What can I do?
 - Validation of confusing emotions is crucial to building trust
 - Debrief with those involved. Review policies and the investigation to prove there was no human error. Do your best to communicate personal autonomy.
 - Add a layer of thorough peer review to rebuild team trust, if affected.
 - Allow involved staff to review/revise policies.
 - It is normal to desire a sense of control and purpose.
 - Support access to EAP or HR trainings
 - Cultivate resiliency by focusing on small wins and praising skills
 - Provide a means for individuals to support each other



Marissa Laureano. (2025, February 21). *Transfusion reactions*. Professional Education. <https://professionaleducation.blood.ca/en/transfusion/clinical-guide/transfusion-reactions>

The Joint Commission. (2025, January 2). *The Sentinel Event Policy (SE)*. Sentinel Event Policy and Procedure. https://www.jointcommission.org/-/media/tjc/documents/resources/patient-safety-topics/sentinel-event/2025/se-4-camlaboratory_se_jan_2025.pdf

Anaphylactic transfusion reactions and Iga deficiency. Professional Education. (2024, July 31). <https://professionaleducation.blood.ca/en/transfusion/publications/anaphylactic-transfusion-reactions-and-iga-deficiency>

Supporting staff when a client dies | groundswell. (n.d.). <https://groundswell.org.uk/wp-content/uploads/2020/10/Supporting-staff-when-a-client-dies-tool-kit.pdf>

Cohn, C. S., Delaney, M., Johnson, S. T., & Katz, L. M. (2020). *Technical Manual* (21st ed.). AABB.

PELLETIER, P. R. (2021). *Aabb Guide to the laboratory evaluation of transfusion reactions*. AMER ASSN BLOOD BANKS.

Standards for Blood Banks and Transfusion Services, 34th Edition. (2024). AABB.

College of American Pathologists Transfusion Medicine Checklist. CAP Accreditation Program. August 2023.

The Joint Commission Accreditation Standards, E-dition. January 2025.

U.S. Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. Notifying FDA of Fatalities Related to Blood Collection or Transfusion; Guidance for Industry. August 2021.



Thank you!

Presentation Resources